Publicis shares crash 12% after creative agencies slump
WPP, Interpublic, and Omnicom also saw stocks slide.
Advertising
Clarity in DTC TV ad drug pricing
Belle Frank is chief strategy officer, global health practice at VMLY&R.
Will increased scrutiny on digital advertising help drive innovation in healthcare marketing?
Traditional digital advertising needs some shaking up, and increased scrutiny just may be the impetus to make that happen, says Lou Iovino, president of Calcium, in this next edition of Outlook 2019, MM&M’s sponsored video series.
Publicis’ Arthur Sadoun: ‘Honestly, my job is tougher than I expected’
Speaking exclusively to Campaign, Sadoun set Publicis Groupe’s full-year results in the context of the changing nature of the advertising business and the challenges facing the company.
Latest MAHF inductees look back on careers well spent
The Medical Advertising Hall of Fame welcomes its first all-women class with Carol DiSanto and Charlene Prounis.
Behind the scenes of Lilly’s ad referencing pricing
Eli Lilly is the first pharma company to react to PhRMA’s revised marketing guidelines, which go into effect in the spring.
7 things to know from Dartmouth’s medical marketing study
Researchers found that spending on medical advertising reached nearly $30 billion in 2016, a $12 billion increase from 1997.
Survey: Attorney ads about bad drugs causing patients to stop taking medicine
Spots that claim a drug has caused serious side effects or death can affect how patients take their medicine and how doctors prescribe it, according to research from the Partnership to Protect Patient Health.
Xeomin launches campaign to end stigma against anti-aging injectables
Xeomin, made by Merz, is hoping to differentiate itself in a market dominated by Allergan’s Botox.
